US HB3276 | 2019-2020 | 116th Congress

Status

Spectrum: Bipartisan Bill
Status: Introduced on June 13 2019 - 25% progression, died in committee
Action: 2019-06-14 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Alters certain requirements and definitions under the Medicaid Drug Rebate Program relating to rebate calculations. Specifically, the bill repeals the requirement that drug manufacturers include the prices of certain authorized generic drugs when determining the average manufacturer price (AMP) of brand-name drugs (also known as a "blended AMP"), and excludes manufacturers from the definition of "wholesalers" for purposes of rebate calculations.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Fair AMP Act Fair and Accurate Medicaid Pricing Act of 2019

Sponsors


History

DateChamberAction
2019-06-14HouseReferred to the Subcommittee on Health.
2019-06-13HouseReferred to the House Committee on Energy and Commerce.
2019-06-13HouseIntroduced in House

Same As/Similar To

HB3253 (Similar To) 2019-08-06 - Became Public Law No: 116-39. (TXT | PDF)
SB1785 (Same As) 2019-06-11 - Read twice and referred to the Committee on Finance.
HB4378 (Related) 2019-09-27 - Became Public Law No: 116-59. (TXT | PDF)

Subjects


US Congress State Sources


Bill Comments

feedback